Credo Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Credo Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$10K	Buy	+399	New	+$9.41K	0.04%	160

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credo Capital Management's ACAD Position: Q4 2013 in Review

Credo Capital Management opened a new position in Acadia Pharmaceuticals (ACAD) in Q4 2013: 399 shares worth $10K. The stake represents 0.04% of the portfolio and ranks #160 among its holdings.

155 funds tracked by Wall St. Rank hold ACAD as of Q4 2013.

Credo Capital Management held 399 shares of Acadia Pharmaceuticals worth $10K as of Q4 2013.
Acadia Pharmaceuticals was a new Credo Capital Management position in Q4 2013.
Acadia Pharmaceuticals made up 0.04% of Credo Capital Management's portfolio in Q4 2013, its #160 holding.
155 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2013.

Based on Credo Capital Management's 13F filing for Q4 2013, filed 24 Jan 2014.